DUBAI, June 16 (Reuters) - QatarEnergy is ready to resume liquefied natural gas production at its Ras Laffan LNG plant very quickly and could reach within a month full output of facilities unaffected ...
Qatar is planning to rapidly boost liquefied natural gas production once the Strait of Hormuz reopens, aiming to restore most of its export capacity within two months, according to people familiar ...
Qatar is preparing to rapidly increase liquefied natural gas production once the Strait of Hormuz reopens, with plans to restore most of its export capacity within two months, Bloomberg reported ...
QatarEnergy is ready to resume liquefied natural gas production at its Ras Laffan LNG plant very quickly and could reach within a month full output of facilities unaffected by Iranian strikes, a ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...
My Alerts is a service for subscribers. Please login or subscribe in order to use My Alerts. QatarEnergy, one of the largest global liquefied natural gas exporters, is preparing to restart gas ...
Iranian strikes have cut about 17% of Doha’s liquefied natural gas (LNG) export capacity, QatarEnergy’s CEO told Reuters in an interview on Thursday. Saad al-Kaabi said the disruption could result in ...
PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...
Qatar’s state-owned energy giant QatarEnergy has stopped all liquefied natural gas (LNG) production, shutting down the country’s entire LNG output after Iranian drone strikes hit its major facilities ...
Our findings suggest that RAS amplification may confer resistance to anti-EGFR antibodies. Assessing RAS amplification status can help clinicians identify patients who may have a reduced benefit from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results